---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-027072"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-12-10T23:59:59+00:00"
generated_at: "2026-05-16T13:40:33.163882+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MAIA touts $50B immunotherapy market; ateganosine gets Fast Track for NSCLC, Phase 3 starting

## Summary
- FDA Fast Track Designation for ateganosine in NSCLC patients resistant to immunotherapy and chemotherapy.
- Initiating Phase 3 THIO-104 trial for advanced NSCLC without actionable mutations and CPI-refractory.
- FDA Orphan Drug Designations for glioblastoma, hepatocellular carcinoma, and small cell lung cancer.
- NSCLC market valued at $34.1B, projected to nearly double to $68.8B by 2033.
- Keytruda generated $29.5B revenue in 2024, with ~30% from NSCLC.

## SEC filing metadata
- accession: 0001493152-25-027072
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315225027072/0001493152-25-027072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315225027072/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-027072
- JSON: https://secwatch.observer/filing/0001493152-25-027072.json
- Plain text: https://secwatch.observer/filing/0001493152-25-027072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.